LIPO vs. SPRB, NRSN, HCWB, FLGC, SNSE, IMNN, BGXX, AIM, HOTH, and CRVO
Should you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include Spruce Biosciences (SPRB), NeuroSense Therapeutics (NRSN), HCW Biologics (HCWB), Flora Growth (FLGC), Sensei Biotherapeutics (SNSE), Imunon (IMNN), Bright Green (BGXX), AIM ImmunoTech (AIM), Hoth Therapeutics (HOTH), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry.
Lipella Pharmaceuticals vs.
Spruce Biosciences (NASDAQ:SPRB) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, community ranking, valuation and profitability.
Spruce Biosciences received 38 more outperform votes than Lipella Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Lipella Pharmaceuticals an outperform vote while only 54.93% of users gave Spruce Biosciences an outperform vote.
Spruce Biosciences currently has a consensus price target of $3.90, suggesting a potential upside of 943.34%. Lipella Pharmaceuticals has a consensus price target of $16.00, suggesting a potential upside of 459.44%. Given Spruce Biosciences' higher probable upside, research analysts clearly believe Spruce Biosciences is more favorable than Lipella Pharmaceuticals.
Spruce Biosciences has a net margin of -555.23% compared to Lipella Pharmaceuticals' net margin of -882.82%. Spruce Biosciences' return on equity of -62.10% beat Lipella Pharmaceuticals' return on equity.
91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 9.1% of Spruce Biosciences shares are owned by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Lipella Pharmaceuticals has lower revenue, but higher earnings than Spruce Biosciences. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.
Spruce Biosciences has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.
In the previous week, Lipella Pharmaceuticals had 1 more articles in the media than Spruce Biosciences. MarketBeat recorded 1 mentions for Lipella Pharmaceuticals and 0 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.00 equaled Lipella Pharmaceuticals'average media sentiment score.
Summary
Spruce Biosciences beats Lipella Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Lipella Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipella Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:LIPO) was last updated on 1/22/2025 by MarketBeat.com Staff
